Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse

Clin Oncol (R Coll Radiol). 2014 Mar;26(3):174. doi: 10.1016/j.clon.2013.11.028. Epub 2013 Dec 22.

Authors

S Di Cosimo¹, D Serpico¹, L Porcu², L Molino¹, G Fanetti¹, V Torri², F de Braud¹

Affiliations

¹ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
² Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri" - IRCCS, Milan, Italy.

PMID: 24368057
DOI: 10.1016/j.clon.2013.11.028

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism*
Female
Humans
Receptor, ErbB-2 / metabolism*

Substances

Antibodies, Monoclonal, Humanized
Receptor, ErbB-2